Pain management in neurocritical care

Neurocritical Care

Volumn 19, Issue 2, 2013, Pages 232-256

  Petzold, Axel ^a   Girbes, Armand ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Analgesia; Intensive care; Neurocritical care; Pain

Indexed keywords

ACICLOVIR; ADRENALIN; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BUPIVACAINE; CORTICOSTEROID; DIHYDROCODEINE; DIHYDROMORPHINE; FENTANYL; FLUVOXAMINE; GABAPENTIN; IBUPROFEN; KETAMINE; KETOROLAC TROMETAMOL; LAMOTRIGINE; LAXATIVE; LIDOCAINE; MEXILETINE; MORPHINE; MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREGABALIN; PROPOFOL; PYRIDOSTIGMINE; REMIFENTANIL; STEROID; TRIPTAN DERIVATIVE; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANALGESIA; ARTERIOVENOUS MALFORMATION; ARTICLE; ARTIFICIAL EMBOLISM; AVULSION INJURY; BEHCET DISEASE; BLEEDING; BRAIN DISEASE; BRAIN ISCHEMIA; BRAIN TOXICITY; CENTRAL PAIN; CEREBRAL SINUS THROMBOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL PRACTICE; CONSCIOUSNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENCEPHALITIS; EPILEPSY; EVOKED CORTICAL RESPONSE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; GUILLAIN BARRE SYNDROME; HEADACHE; HEALTH CARE COST; HISTAMINE RELEASE; HUMAN; HYDROCEPHALUS; HYPOTENSION; IATROGENIC DISEASE; INTENSIVE CARE; KIDNEY DISEASE; LIVER FAILURE; MALARIA; MENINGITIS; MULTIPLE SCLEROSIS; MUSCULOSKELETAL PAIN; MYASTHENIA GRAVIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHIC PAIN; NOCICEPTIVE PAIN; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PHONOPHOBIA; PHOTOPHOBIA; POEMS SYNDROME; POLIOMYELITIS; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRION DISEASE; PRIORITY JOURNAL; RADIOSURGERY; RESPIRATION DEPRESSION; RIGIDITY; SECONDARY HEADACHE; SENSORY STIMULATION; SIDE EFFECT; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; SYRINGOMYELIA; TENSION HEADACHE; THROMBOCYTE FUNCTION; THYMECTOMY; TRAUMATIC BRAIN INJURY; VASCULAR HEADACHE; VASCULITIS; VISUAL ANALOG SCALE; WEST NILE FEVER;

ANALGESICS; CHRONIC PAIN; CRITICAL CARE; HUMANS; NEURALGIA; PAIN MANAGEMENT; PAIN MEASUREMENT;

EID: 84885190674     PISSN: 15416933     EISSN: 15560961     Source Type: Journal    
DOI: 10.1007/s12028-013-9851-0     Document Type: Article

References (356)

1. Puntillo K. Pain experiences of intensive care unit patients. Heart Lung. 1990;19:526-33.
2. Bergbom-Engberg I, Haljamae H. Assessment of patients' experience of discomforts during respirator therapy. Crit Care Med. 1989;17:1068-72.
3. Cook D, Meade M, Perry A. Qualitative studies on the patient's experience of weaning from mechanical ventilation. Chest. 2001;120:469S-73S.
4. Novaes M, Knobel E, Bork A, Pavao O, Nogueira-Martins L, Ferraz M. Stressors in ICU: perception of the patient, relatives and health care team. Intensive Care Med. 1999;25:1421-6.
5. Carroll K, Atkins P, Herold G, et al. Pain assessment and management in critically ill postoperative and trauma patients: a multisite study. Am J Crit Care. 1999;8:105-17.
6. Ferguson J, Gilroy D, Puntillo K. Dimensions of pain and analgesic administration associated with coronary artery by pass grafting in an Australian intensive care unit. J Adv Nurs. 1997;26:1065-72.
7. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med. 2006;34:1691-9.
8. Teitelbaum JS, Ayoub O, Skrobik Y. A critical appraisal of sedation, analgesia and delirium in neurocritical care. Can J Neurol Sci. 2011;38:815-25.
9. Barber J. Pharmacologic management of integrative brain failure. Crit Care Nurs Q. 2003;26:192-207.
10. Mateo O, Krenzischek D. A pilot study to assess the relationship between behavioral manifestations and self-report of pain in postanesthesia care unit patients. J Post Anesth Nurs. 1992;7:15-21.
11. Puntillo K, Miaskowski C, Kehrle K, Stannard D, Gleeson S, Nye P. Relationship between behavioral and physiological indicators of pain, critical care patients' self-reports of pain, and opioid administration. Crit Care Med. 1997;25:1159-66.
12. Payen J, Bru O, Bosson J, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med. 2001;29:2258-63.
13. Nelson J, Meier D, Oei E, et al. Self-reported symptom experience of critically ill cancer patients receiving intensive care. Crit Care Med. 2001;29:277-82.
14. Turner J, Briggs S, Springhorn H, Potgieter P. Patients' recollection of intensive care unit experience. Crit Care Med. 1990;18:966-8.
15. Melzack R, Katz J. Pain assessment in adult patients. In: McMahon S, Koltzenburg M, editors. Textbook of pain. Philadelphia: Elsevier Churchill Livingstone; 2006. p. 291-304.
16. Walder B, Tramer M. Analgesia and sedation in critically ill patients. Swiss Med Wkly. 2004;134:333-46.
17. Peter E, Janssen P, Grange C, Douglas M. Ibuprofen versus acetaminophen with codeine for the relief of perineal pain after childbirth: a randomized controlled trial. CMAJ. 2001;165:1203-9.
18. Bonica J. Semantic, epidemiologic, and educational issues of central pain. In: Casey K, editor. Pain and central nervous system disease: the central pain syndromes. New York: Raven Press; 1991. p. 13-29.
19. Bovie J. Hyperalgesia and allodynia. In: Willis W, editor. Hyperalgesia and allodynia in patients with CNS lesions. New York: Raven Press; 1992. p. 363-73.
20. Tsubokawa T, Katayama Y. Motor cortex stimulation in persistent pain management. In: Gildenberg P, Tasker R, editors. Textbook of stereotactic and functional neurosurgery. New York: McGraw-Hill; 1998. p. 1547-56.
21. Hamill-Ruth R, Marohn M. Evaluation of pain in the critically ill patient. Crit Care Clin. 1999;15:35-54, v-vi.
22. Epstein J, Breslow M. The stress response of critical illness. Crit Care Clin. 1999;15:17-33, v.
23. Desai P. Pain management and pulmonary dysfunction. Crit Care Clin. 1999;15:151-66, vii.
24. Gust R, Pecher S, Gust A, Hoffmann V, Bohrer H, Martin E. Effect of patient-controlled analgesia on pulmonary complications after coronary artery bypass grafting. Crit Care Med. 1999;27:2218-23.
25. Mascia M, Koch M, Medicis J. Pharmacoeconomic impact of rational use guidelines on the provision of analgesia, sedation, and neuromuscular blockade in critical care. Crit Care Med. 2000;28:2300-6.
26. MacLaren R, Sullivan PW. Economic evaluation of sustained sedation/analgesia in the intensive care unit. Expert Opin Pharmacother. 2006;7:2047-68.
27. Jönsson A, Lindgren I, Hallstrom B, Norrving B, Lindgren A. Prevalence and intensity of pain after stroke: a population based study focusing on patients' perspectives. J Neurol Neurosurg Psychiatry. 2006;77:590-5.
28. Kumral E, Kocaer T, Ertubey N, Kumral K. Thalamic hemorrhage. A prospective study of 100 patients. Stroke. 1995;26:964-70.
29. Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen T. Incidence of central post-stroke pain. Pain. 1995;61:187-93.
30. Widar M, Samuelsson L, Karlsson-Tivenius S, Ahlstrom G. Longterm pain conditions after a stroke. J Rehabil Med. 2002;34:165-70.
31. Hansson P. Post-stroke pain case study: clinical characteristics, therapeutic options and long-term follow-up. Eur J Neurol. 2004;11(Suppl 1):22-30.
32. Gamble G, Barberan E, Bowsher D, Tyrrell P, Jones A. Post stroke shoulder pain: more common than previously realized. Eur J Pain. 2000;4:313-305.
33. Langhorne P, Stott D, Robertson L, et al. Medical complications after stroke: a multicenter study. Stroke. 2000;31:1223-9.
34. McLean D. Medical complications experienced by a cohort of stroke survivors during inpatient, tertiary-level stroke rehabilitation. Arch Phys Med Rehabil. 2004;85:466-9.
35. Dejerine J, Roussy J. Le syndrome thalamique. Rev Neurol. 1906;14:521-32.
36. Boivie J. Central pain. In: McMahon S, Koltzenburg M, editors. Textbook of pain. 5th ed. Philadelphia: Elsevier Churchill Livingstone; 2006. p. 1057-74.
37. Foix C, Chavany J, Lévy M. Syndrome pseudo-thalamique d'origine pariétale. Lésion de l'artère du sillon interpariétale. CR Soc Neurol. 1927;35:68-78.
38. Cassinari V, Pagni C. Central pain. A neurosurgical survey. Cambridge: Harvard University Press; 1969.
39. Bowsher D, Leijon G, Thuomas K. Central poststroke pain: correlation of MRI with clinical pain characteristics and sensory abnormalities. Neurology. 1998;51:1352-8.
40. Chen W, Tseng Y, Lui C, Liu J. Episodic pain syndrome restricted cheiro-oral region associated with pontine lesion. Brain Inj. 2005;19:949-53.
41. Masjuan J, Baron M, Lousa M, Gobernado J. Isolated pontine infarctions with prominent ipsilateral midfacial sensory signs. Stroke. 1997;28:649-51.
42. Mallory GW, Abulseoud O, Hwang SC, et al. The nucleus accumbens as a potential target for central poststroke pain. Mayo Clin Proc. 2012;87:1025-31.
43. Boivie J, Leijon G, Johansson I. Central post-stroke pain: a study of the mechanisms through analysis of the sensory abnormalities. Pain. 1989;36:173-85.
44. Frese A, Husstedt I, Ringelstein E, Evers S. Pharmacologic treatment of central post-stroke pain. Clin J Pain. 2006;22:252-60.
45. Carter B, Medzihradsky F. Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells. Mol Pharmacol. 1993;43:465-73.
46. Willoch F, Tolle T, Wester H, et al. Central pain after pontine infarction is associated with changes in opioid receptor binding: A PET study with C-11-diprenorphine. Am J Neuroradiol. 1999;20:686-90.
47. Riddoch G. The clinical features of central pain. Lancet. 1938;234:1093-8, 1150-6, 1205-9.
48. Siniscalchi A, Gallelli L, DeSarro G, Malferrari G, Santangelo E. Antiepileptic drugs for central post-stroke pain management. Pharmacol Res. 2012;65:171-5.
49. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, DePuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26:1051-70.
50. Bowsher D. The management of central post-stroke pain. Postgrad Med J. 1995;71:598-604.
51. Fregni F, Boggio P, Lima M, et al. Asham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain. 2006;122:197-209.
52. Son B, Lee S, Choi E, Sung J, Hong J. Motor cortex stimulation for central pain following a traumatic brain injury. Pain. 2006;123:210-6.
53. Hirayama A, Saitoh Y, Kishima H, et al. Reduction of intractable deafferentation pain by navigation-guided repetitive transcranial magnetic stimulation of the primary motor cortex. Pain. 2006;122:22-7.
54. Lefaucheur J, Drouot X, Menard-Lefaucheur I, et al. Neurogenic pain relief by repetitive transcranial magnetic cortical stimulation depends on the origin and the site of pain. J Neurol Neurosurg Psychiatry. 2004;75:612-6.
55. Khedr E, Kotb H, Kamel N, Ahmed M, Sadek R, Rothwell J. Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain. J Neurol Neurosurg Psychiatry. 2005;76:833-8.
56. Lefaucheur J, Drouot X, Keravel Y, Nguyen J. Pain relief induced by repetitive transcranial magnetic stimulation of precentral cortex. Neuroreport. 2001;12:2963-5.
57. van Gijn J, Rinkel G. Subarachnoid haemorrhage: diagnosis, causes and management. Brain. 2001;124:249-78.
58. Linskey M, Sekhar L, Hirsch WLJ, Yonas H, Horton J. Aneurysms of the intracavernous carotid artery: natural history and indications for treatment. Neurosurgery. 1990;26:933-7.
59. Wijdicks E, Kerkhoff H, van Gijn J. Long-term follow-up of 71 patients with thunderclap headache mimicking subarachnoid haemorrhage. Lancet. 1988;2:68-70.
60. Edlow J, Caplan L. Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl J Med. 2000;342:29-36.
61. Petzold A, Keir G, Sharpe L. Spectrophotometry for xanthochromia. N Engl J Med. 2004;351:1695-6.
62. Petzold A, Worthington V, Kerr M, Appleby I, Kitchen N, Smith M. Cerebrospinal fluid ferritin levels, a sensitive diagnostic test in delayed presenting subarachnoid haemorrhage. J Stroke Cerebrovasc Dis. 2011;20:489-93.
63. Fernandez-Melo R, Lopez-Flores G, Cruz-Garcia O, et al. [The diagnosis of arteriovenous malformations of the brain]. Rev Neurol. 2003;37:870-8.
64. Hofmeister C, Stapf C, Hartmann A, et al. Demographic, morphological, and clinical characteristics of 1289 patients with brain arteriovenous malformation. Stroke. 2000;31:1307-10.
65. Stapf C, Mohr J, Sciacca R, et al. Incident hemorrhage risk of brain arteriovenous malformations located in the arterial border zones. Stroke. 2000;31:2365-8.
66. Stapf C, Khaw A, Sciacca R, et al. Effect of age on clinical and morphological characteristics in patients with brain arteriovenous malformation. Stroke. 2003;34:2664-9.
67. Graham GD. Arteriovenous Malformations in the Brain. Curr Treat Options Neurol. 2002;4:435-44.
68. Spagnuolo E, Lemme-Plaghos L, Revilla F, Quintana L, and Antico J. [Recommendation for the management of the brain arteriovenous malformations]. Neurocirugia (Astur). 2009;20:5-14, discussion 14.
69. Ogilvy CS, Stieg PE, Awad I, et al. AHA scientific statement: recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke. 2001;32:1458-71.
70. Fukuhara T, McKhann GM 2nd, Santiago P, Eskridge J, Loeser J, Winn H. Resolution of central pain after embolization of an arteriovenous malformation. Case report. J Neurosurg. 1999;90:575-9.
71. Canavero S, Bonicalzi V. Resolution of central pain. J Neurosurg. 1999;91:715-6.
72. Spiller W. Thrombosis of the cervical anterior median artery: syphilitic acute anterior poliomyelitis. J Nerv Ment Dis. 1909;36:601-13.
73. Deller JJJ, Scalettar R, Levens A. Pain as a manifestation of acute anterior-spinal-artery thrombosis. N Engl J Med. 1960;262:1078-9.
74. Cheng MY, Lyu RK, Chang YJ, et al. Spinal cord infarction in Chinese patients. Clinical features, risk factors, imaging and prognosis. Cerebrovasc Dis. 2008;26:502-8.
75. Kumral E, Polat F, Güllüoglu H, Uzunköprü C, Tuncel R, Alpaydin S. Spinal ischaemic stroke: clinical and radiological findings and short-term outcome. Eur J Neurol. 2011;18:232-9.
76. Novy J, Carruzzo A, Maeder P, Bogousslavsky J. Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol. 2006;63:1113-20.
77. Masson C, Pruvo J, Meder J, et al. Spinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. J Neurol Neuro surg Psychiatry. 2004;75:1431-5.
78. Schaller B, Lyrer P. [Anterior spinal artery syndrome: an important differential diagnosis of acute non-traumatic transverse spinal cord syndrome]. Schweiz Rundsch Med Prax. 2001;90:1420-7.
79. Latronico N, Fassini P, Antonini B, Gasparotti R. A pain in the neck. Lancet. 2002;359:1206.
80. Mittal MK, Rabinstein AA, Wijdicks EF. Pearls & oysters: acute spinal cord infarction following endoscopic ultrasound-guided celiac plexus neurolysis. Neurology. 2012;78:e57-9.
81. Jacob JT, Tanaka S, Wood CP, Wijdicks EF, Lanzino G. Acute epidural spinal hemorrhage from vasculitis: resolution with immunosuppression. Neurocrit Care. 2012;16:311-5.
82. Serrano-Pozo A, Nevado-Portero J, Sanz-Fernandez G, Martinez-Fernandez E. Neurological picture. Spinal anterior artery territory infarction simulating an acute myocardial infarction. J Neurol Neurosurg Psychiatry. 2005;76:1584.
83. de la Sayette V, Leproux F, Letellier P. Cervical cord and dorsal medullary infarction presenting with retro-orbital pain. Neurology. 1999;53:632-4.
84. de la Sayette V, Schaeffer S, Coskun O, Leproux F, Defer G. Cluster headache-like attack as an opening symptom of a unilateral infarction of the cervical cord: persistent anaesthesia and dysaesthesia to cold stimuli. J Neurol Neurosurg Psychiatry. 1999;66:397-400.
85. Triggs W, Beric A. Sensory abnormalities and dysaesthesias in the anterior spinal artery syndrome. Brain. 1992;115(Pt 1):189-98.
86. Robertson CE, Brown Jr RD, Wijdicks EFM, Rabinstein AA. Recovery after spinal cord infarcts: long-term outcome in 115 patients. Neurology. 2012;78:114-21.
87. Cumurciuc R, Crassard I, Sarov M, Valade D, Bousser M. Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases. J Neurol Neurosurg Psychiatry. 2005;76:1084-7.
88. Gameiro J, Ferro JM, Canhão P, Stam J, Barinagarrementeria F, Lindgren A, et al. Prognosis of cerebral vein thrombosis presenting as isolated headache: early vs late diagnosis. Cephalalgia. 2012;32:407-12
89. Canhao P, Ferro JM, Lindgren AG, Bousser MG, Stam J, Barinagarrementeria F. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36:1720-5.
90. Petzold A, Smith M. High intracranial pressure, brain herniation and death in cerebral venous thrombosis. Stroke. 2006;37:331-2.
91. Einhäupl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17:1229-35.
92. Ferro JM, Crassard I, Coutinho JM, et al. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke. 2011;42:2825-31.
93. Roberts DJ, Hall RI, Kramer AH, Robertson HL, Gallagher CN, Zygun DA. Sedation for critically ill adults with severe traumatic brain injury: a systematic review of randomized controlled trials. Crit Care Med. 2011;39:2743-51.
94. Canhäo P, Abreu LF, Ferro JM, et al. Safety of lumbar puncture in patients with cerebral venous thrombosis. Eur J Neurol. 2013. doi: 10.1111/ene.12136.
95. Collins M, Periquet M. Non-systemic vasculitic neuropathy. Curr Opin Neurol. 2004;17:587-98.
96. Shrestha S, Sumingan N, Tan J, Althous H, McWilliam L, Ballardie F. Henoch Schonlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM. 2006;99:253-65.
97. Kleppel J, Lincoln A, Winston F. Assessing head-injury survivors of motor vehicle crashes at discharge from trauma care. Am J Phys Med Rehabil. 2002;81:114-22, 142.
98. Walker W. Pain pathoetiology after TBI: neural and nonneural mechanisms. J Head Trauma Rehabil. 2004;19:72-81.
99. Garland D, Bailey S. Undetected injuries in head-injured adults. Clin Orthop Relat Res. 1981;(155):162-65.
100. Walker W, Seel R, Curtiss G, Warden D. Headache after moderate and severe traumatic brain injury: a longitudinal analysis. Arch Phys Med Rehabil. 2005;86:1793-1800.
101. Hillier S, Sharpe M, Metzer J. Outcomes 5 years post-traumatic brain injury(with further reference to neurophysical impairment and disability). Brain Inj. 1997;11:661-75.
102. Olver J, Ponsford J, Curran C. Outcome following traumatic brain injury: a comparison between 2 and 5 years after injury. Brain Inj. 1996;10:841-8.
103. Minderhoud JM, Boelens ME, Huizenga J, Saan RJ. Treatment of minor head injuries. Clin Neurol Neurosurg. 1980;82:127-40.
104. Denker PG. The postconcussion syndrome: prognosis and evaluation of the organic factors. NY State J Med. 1944;44:379-84.
105. Keidel M, Diener HC. [Post-traumatic headache]. Nervenarzt. 1997;68:769-77.
106. Rimel RW, Giordani B, Barth JT, Boll TJ, Jane JA. Disability caused by minor head injury. Neurosurgery. 1981;9:221-8.
107. Rutherford WH, Merrett JD, McDonald JR. Symptoms at one year following concussion from minor head injuries. Injury. 1979;10:225-30.
108. Faux S, Sheedy J. A prospective controlled study in the prevalence of posttraumatic headache following mild traumatic brain injury. Pain Med. 2008;9:1001-11.
109. Iverson G. Outcome from mild traumatic brain injury. Curr Opin Psychiatry. 2005;18:301-17.
110. Nicholson K. Pain, cognition and traumatic brain injury. NeuroRehabilitation. 2000;14:95-103.
111. Mickeviciene D, Schrader H, Obelieniene D, et al. A controlled prospective inception cohort study on the post-concussion syndrome outside the medicolegal context. Eur J Neurol. 2004;11:411-9.
112. HC Millar. Accident neurosis. BMJ. 1961;i:919-25, 992-8.
113. Baandrup L, Jensen R. Chronic post-traumatic headache - a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia. 2005;25:132-8.
114. Lane JC, Arciniegas DB. Post-traumatic Headache. Curr Treat Options Neurol. 2002;4:89-104.
115. Goadsby PJ. Is medication-overuse headache a distinct biological entity? Nat Clin Pract Neurol. 2006;2:401.
116. Nashold BSJ, Ostdahl R. Dorsal root entry zone lesions for pain relief. J Neurosurg. 1979;51:59-69.
117. Raisman G, Carlstedt T, Choi D, Li Y. Clinical prospects for transplantation of OECs in the repair of brachial and lumbosacral plexus injuries: Opening a door. Exp Neurol. 2010;229:168-73.
118. Sindou M, Blondet E, Emery E, Mertens P. Microsurgical lesioning in the dorsal root entry zone for pain due to brachial plexus avulsion: a prospective series of 55 patients. J Neurosurg. 2005;102:1018-28.
119. Tomas R, Haninec P. Dorsal root entry zone (DREZ) localization using direct spinal cord stimulation can improve results of the DREZ thermocoagulation procedure for intractable pain relief. Pain. 2005;116:159-63.
120. Samii M, Bear-Henney S, Ludemann W, Tatagiba M, Blomer U. Treatment of refractory pain after brachial plexus avulsion with dorsal root entry zone lesions. Neurosurgery. 2001;48:1269-75.
121. Rath S, Seitz K, Soliman N, Kahamba J, Antoniadis G, Richter H. DREZ coagulations for deafferentation pain related to spinal and peripheral nerve lesions: indication and results of 79 consecutive procedures. Stereotact Funct Neurosurg. 1997;68:161-7.
122. Thomas D, Kitchen N. Long-term follow up of dorsal root entry zone lesions in brachial plexus avulsion. J Neurol Neurosurg Psychiatry. 1994;57:737-8.
123. Raslan AM, Burchiel KJ. Neurosurgical advances in cancer pain management. Curr Pain Headache Rep. 2010;14:477-82.
124. Moossy J, Nashold BSJ, Osborne D, Friedman A. Conus medullaris nerve root avulsions. J Neurosurg. 1987;66:835-41.
125. Ravenscroft A, Ahmed Y, Burnside I. Chronic pain after SCI. A patient survey. Spinal Cord. 2000;38:611-4.
126. Donnelly C, Eng J. Pain following spinal cord injury: the impact on community reintegration. Spinal Cord. 2005;43:278-82.
127. Kennedy P, Frankel H, Gardner B, Nuseibeh I. Factors associated with acute and chronic pain following traumatic spinal cord injuries. Spinal Cord. 1997;35:814-7.
128. New P, Lim T, Hill S, Brown D. A survey of pain during rehabilitation after acute spinal cord injury. Spinal Cord. 1997;35:658-63.
129. Siddall P, Taylor D, McClelland J, Rutkowski S, Cousins M. Pain report and the relationship of pain to physical factors in the first 6 months following spinal cord injury. Pain. 1999;81:187-97.
130. Werhagen L, Budh C, Hultling C, Molander C. Neuropathic pain after traumatic spinal cord injury-relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord. 2004;42:665-73.
131. Siddall P, McClelland J, Rutkowski S, Cousins M. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain. 2003;103:249-57.
132. Siddall P, Loeser J. Pain following spinal cord injury. Spinal Cord. 2001;39:63-73.
133. Eide P, Stubhaug A, Stenehjem A. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-d-aspartate receptor activation. Neurosurgery. 1995;37:1080-7.
134. Kalpakjian CZ, Khoury PE, Chiodo AE, Kratz AL. Patterns of pain across the acute SCI rehabilitation stay: evidence from hourly ratings. Spinal Cord. 2012;151:289-94.
135. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375-83.
136. Haller H, Leblhuber F, Trenkler J, Schmidhammer R. Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin. J Neural Transm. 2003;110:977-81.
137. Tai Q, Kirshblum S, Chen B, Millis S, Johnston M, DeLisa J. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25:100-5.
138. Teasell RW, Mehta S, Aubut JAL, et al. A systematic review of pharmacologic treatments of pain after spinal cord injury. Arch Phys Med Rehabil. 2010;91:816-31.
139. Widerstrom-Noga E, Cruz-Almeida Y, Krassioukov A. Is there a relationship between chronic pain and autonomic dysreflexia in persons with cervical spinal cord injury? J Neurotrauma. 2004;21:195-204.
140. Denkers M, Biagi H, Ann O'Brien M, Jadad A, Gauld M. Dorsal root entry zone lesioning used to treat central neuropathic pain in patients with traumatic spinal cord injury: a systematic review. Spine. 2002;27:E177-84
141. Nashold BSJ, Bullitt E. Dorsal root entry zone lesions to control central pain in paraplegics. J Neuro surg. 1981;55:414-409.
142. Sindou M, Mertens P, Wael M. Microsurgical DREZotomy for pain due to spinal cord and/or cauda equina injuries: long-term results in a series of 44 patients. Pain. 2001;92:159-71.
143. Milhorat T, Kotzen R, Mu H, Capocelli ALJ, Milhorat R. Dysesthetic pain in patients with syringomyelia. Neurosurgery. 1996;38:940-6.
144. Ducreux D, Attal N, Parker F, Bouhassira D. Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia. Brain. 2006;129:963-76.
145. Attal N, Parker F, Tadie M, Aghakani N, Bouhassira D. Effects of surgery on the sensory deficits of syringomyelia and predictors of outcome: a long term prospective study. J Neurol Neurosurg Psychiatry. 2004;75:1025-30.
146. Agarwal-Kozlowski K, Lorke DE, Habermann CR, Schulte am Esch J, Beck H. Interventional management of intractable sympathetically mediated pain by computed tomography-guided catheter implantation for block and neuroablation of the thoracic sympathetic chain: technical approach and review of 322 procedures. Anaesthesia. 2011;66:699-708.
147. Michael BD, Sidhu M, Stoeter D, et al. Acute central nervous system infections in adults - a retrospective cohort study in the NHS North West region. QJM. 2010;103:749-58.
148. van de Beek D, de Gans J, Tunkel AR. Wijdicks EFM. Community acquired bacterial meningitis in adults. N Engl J Med. 2006;354:44-53.
149. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351:1849-59.
150. Hoffmann O, Dirnagl U, Weber J. The trigeminovascular system in bacterial meningitis. Microsc Res Tech. 2004;53:188-192.
151. Benninger F, Steiner I. Steroids in bacterial meningitis: yes. J Neural Transm. 2013;120:339-42.
152. Pfausler B, Schmutzhard E. Controversies in neurology, Vienna, 2012: steroids in bacterial meningitis: no. J Neural Transm. 2013;120:343-46.
153. Huang Y, Cai X, Song X, et al. Steroids for preventing recurrence of acute severe migraine headaches: a meta-analysis. Eur J Neurol. 2013. doi: 10.1111/ene.12155.
154. Jereb M, Lainscak M, Marin J, Popovic M. Herpes simplex virus infection limited to the brain stem. Wien Klin Wochenschr. 2005;117:495-9.
155. Tyler K. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes. 2004;11(Suppl 2):57A-64A.
156. Orton S, Stramer S, Dodd R. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion. 2006;46:272-207.
157. Hayes E. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11:1174-9.
158. Mackenzie J, Gubler D, Petersen L. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. 2004;10:S98-109.
159. Leis A, Stokic D. Neuromuscular Manifestations of Human West Nile Virus Infection. Curr Treat Options Neurol. 2005;7:15-22.
160. Solomon T. Flavivirus encephalitis. N Engl J Med. 2004;351:370-8.
161. Solomon T. Exotic and emerging viral encephalitides. Curr Opin Neurol. 2003;16:411-8.
162. Kennedy P. Human African trypanosomiasis-neurological aspects. J Neurol. 2006;253:411-6.
163. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop. 2006;97:55-64.
164. Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage Human African trypanosomiasis. Cochrane Database Syst Rev. 2010;8:CD006201.
165. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health. 2001;6:390-400.
166. White N. The treatment of malaria. N Engl J Med. 1996;335:800-6.
167. Idro R, Jenkins N, Newton C. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 2005;4:827-40.
168. da Silva-Nunes M, Ferreira MU. Clinical spectrum of uncomplicated malaria in semi-immune Amazonians: beyond the 'symptomatic" vs "asymptomatic" dichotomy. Mem Inst Oswaldo Cruz. 2007;102:341-7.
169. Wiwanitkit V. Headache and malaria: a brief review. Acta Neurol Taiwan. 2009;18:56-9.
170. Adudu OP, Ogunrin OA, Adudu OG. Morbidity and mortality patterns among neurological patients in the intensive care unit of a tertiary health facility. Ann Afr Med. 2007;6:174-9.
171. Sarkar PK, Ahluwalia G, Vijayan VK, Talwar A. Critical care aspects of malaria. J Intensive Care Med. 2010;25:93-103.
172. Sahu S, Mohanty NK, Rath J, Patnaik SB. Spectrum of malaria complications in an intensive care unit. Singapore Med J. 2010;51:226-9.
173. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010;10:405-16.
174. Xiao SH, Keiser J, Chen MG, Tanner M, Utzinger J. Research and development of antischistosomal drugs in the People's Republic of China - a 60-year review. Adv Parasitol. 2010;73:231-95.
175. Garcia LS. Malaria. Clin Lab Med. 2010;30:93-129.
176. Yamamoto K, Chiba H, Ishitobi M, Nakagawa H, Ogawa T, Ishii K. Acute encephalopathy with bilateral striatal necrosis: favourable response to corticosteroid therapy. Eur J Paediatr Neurol. 1997;1:41-5.
177. Casey S, Sampaio R, Michel E, Truwit C. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000;21:1199-206.
178. Bakshi R, Bates V, Mechtler L, Kinkel P, Kinkel W. Occipital lobe seizures as the major clinical manifestation of reversible posterior leukoencephalopathy syndrome: magnetic resonance imaging findings. Epilepsia. 1998;39:295-9.
179. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494-500.
180. Elahi A, Kelkar P, St Louis E. Posterior reversible encephalopathy syndrome as the initial manifestation of Guillain-Barré Syndrome. Neurocrit Care. 2004;1:465-8.
181. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980-2.
182. Custodio C, Basford J. Delayed postanoxic encephalopathy: a case report and literature review. Arch Phys Med Rehabil. 2004;85:502-5.
183. Hendrickson R, Hedges J. Introduction - what critical care practitioners should know about terrorism agents. Crit Care Clin. 2005;21:641-52.
184. Baker D. Critical care requirements after mass toxic agent release. Crit Care Med. 2005;33:S66-74.
185. Ratnaike R. Acute and chronic arsenic toxicity. Postgrad Med J. 2003;79:391-6.
186. Rusyniak D, Furbee R, Kirk M. Thallium and arsenic poisoning in a small midwestern town. Ann Emerg Med. 2002;39:307-11.
187. Lidsky T, Schneider J. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain. 2003;126:5-19.
188. Ehde D, Gibbons L, Chwastiak L, Bombardier C, Sullivan M, Kraft G. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler. 2003;9:605-11.
189. Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13:320.
190. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand. 1991;84:197-200.
191. Howard R, Wiles C, Hirsch N, Loh L, Spencer G, Newsom-Davis J. Respiratory involvement in multiple sclerosis. Brain Behav Evol. 1992;115(Pt 2):479-94
192. Gosselink R, Kovacs L, Ketelaer P, Carton H, Decramer M. Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients. Arch Phys Med Rehabil. 2000;81:747-51.
193. Welch SP, Sim-Selley LJ, Selley DE. Sphingosine-1-phosphate receptors as emerging targets for treatment of pain. Biochem Pharmacol. 2012;84:1551-62.
194. Siva A, Saip S. The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis. J Neurol. 2009;256:513-29.
195. Aykutlu E, Baykan B, Akman-Demir G, Topcular B, Ertas M. Headache in Behcet's disease. Cephalalgia. 2006;26:180-6.
196. Saip S, Siva A, Altintas A, et al. Headache in Behcet's syndrome. Headache. 2005;45:911-9.
197. Kidd D. The prevalence of headache in Behcet's syndrome. Adv Exp Med Biol. 2003;528:377-9.
198. Nitecki S, Ofer A, Karram T, Schwartz H, Engel A, Hoffman A. Abdominal aortic aneurysm in Behcet's disease: new treatment options for an old and challenging problem. Isr Med Assoc J. 2004;6:152-5.
199. Lee C, Lee J, Lee W, et al. Aortic valve involvement in Behcet's disease. A clinical study of 9 patients. Korean J Intern Med. 2002;17:51-6.
200. Basak M, Gul S, Yazgan Y, et al. A case of rapidly progressive pulmonary aneurysm as a rare complication of Behcet's syndrome - a case report. Angiology. 1998;49:403-8.
201. Paccagnella A, Turolla L, Zanardo G, et al. Fatal progression of Behcet's disease after cardiac surgery. Thorac Cardiovasc Surg. 1989;37:320-1.
202. Alpsoy E, Akman A. Behçet's disease: an algorithmic approach to its treatment. Arch Dermatol Res. 2009;301:693-702.
203. Gonzales G, Tuttle S, Thaler H, Manfredi P. Central pain in cancer patients. J Pain. 2003;4:351-4.
204. Rees J. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 2):ii43-50.
205. Lundberg P. Creutzfeldt-Jakob disease in Sweden. J Neurol Neurosurg Psychiatry. 1998;65:836-41.
206. Palmirotta R, Ludovici G, Egeo G, et al. Prion protein gene M129V polymorphism and variability in age at migraine onset. Headache. 2013;53:540-5.
207. Goadsby PJ, Cittadini E, Burns B, Cohen AS. Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. Curr Opin Neurol. 2008;21:323-30.
208. © syndrome. J Neurol. 2006;253:214-8.
209. Pan C, Tseng T, Lin Y, Chiang M, Lin W, Hsieh S. Cutaneous innervation in Guillain-Barré syndrome: pathology and clinical correlations. Brain. 2003;126:386-97.
210. Moulin D, Hagen N, Feasby T, Amireh R, Hahn A. Pain in Guillain-Barré syndrome. Neurology. 1997;48:328-31.
211. Ruts L, Drenthen J, Jongen JLM, et al. Pain in Guillain-Barré syndrome. A long-term follow-up study. Neurology. 2010;75:1439-47.
212. Ropper A, Shahani B. Pain in Guillain-Barré syndrome. Arch Neurol. 1984;41:511-4.
213. Ishii W, Sekijima Y, Hattori T, Tsuyuzaki J, Ikeda S. [A case of Guillain-Barré syndrome starting from severe upper back pain]. No To Shinkei. 2003;55:963-6.
214. Li P, Chang H, Huang H, Lin J. Guillain-Barré syndrome presenting with severe pain: report of one case. Acta Paediatr Taiwan. 2000;41:33-35.
215. Murray NM, Wade DT. The sural sensory action potential in Guillain-Barré syndrome. Muscle Nerve. 1980;3:444.
216. Rostasy K, Huppke P, Beckers B, et al. Acute motor and sensory axonal neuropathy (AMSAN) in a 15-year-old boy presenting with severe pain and distal muscle weakness. Neuropediatrics. 2005;36:260-4.
217. Wilmshurst J, Thomas N, Robinson R, Bingham J, Pohl K. Lower limb and back pain in Guillain-Barré syndrome and associated contrast enhancement in MRI of the cauda equina. Acta Paediatr. 2001;90:691-4.
218. Pandey C, Bose N, Garg G, et al. Gabapentin for the treatment of pain in Guillain-Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95:1719-23.
219. Tripathi M, Kaushik S. Carbamezapine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med. 2000;28:655-8.
220. Pandey C, Raza M, Tripathi M, Navkar D, Kumar A, Singh U. The comparative evaluation of gabapent in and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Anesth Analg. 2005;101:220-5.
221. Hughes R, Wijdicks E, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62:1194-8.
222. Thomaides T, Kerezoudi E, Zoukos Y, Chaudhuri K. Thermal thresholds and motor sensory conduction measurements in Guillain-Barré syndrome: 12-month follow-up study. Eur Neurol. 1992;32:274-80.
223. Bernsen R, Jager A, Schmitz P, van der Meche F. Long-term sensory deficit after Guillain-Barré syndrome. J Neurol. 2001;248:483-6.
224. Kennedy W, Wendelschafer-Crabb G. The innervation of human epidermis. J Neurol Sci. 1993;115:184-90.
225. Kennedy W, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology. 1996;47:1042-8.
226. McCarthy B, Hsieh S, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology. 1995;45:1848-55.
227. Griffin J, McArthur J, Polydefkis M. Assessment of cutaneous innervation by skin biopsies. Curr Opin Neurol. 2001;14:655-9.
228. Steck A, Erne B, Gabriel J, Schaerenwiemers N. Paraproteinaemic neuropathies. Brain Pathology. 1999;9:361-8.
229. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2006;11:9-19.
230. Steck AJ, Czaplinski A, Renaud S. Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update. Neurotherapeutics. 2008;5:528-34.
231. Créange A, Chater A, Brouet JC, et al. A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation. Nat Clin Pract Neurol. 2008;4:686-91.
232. Goto H, Nishio M, Kumano K, Fujimoto K, Yamaguchi K, Koike T. Discrepancy between disease activity and levels of vascular endothelial growth factor in a patient with POEMS syndrome successfully treated with autologous stem-cell transplantation. Bone Marrow Transplant. 2008;42:627-9.
233. Wilkins K, Bulkley G. Thymectomy in the integrated management of myasthenia gravis. Adv Surg. 1999;32:105-33.
234. Toker A, Eroglu O, Ziyade S et al. Comparison of early postoperative results of thymectomy: partial sternotomy vs videothoracoscopy. Thorac Cardiovasc Surg. 2005;53:110-3.
235. Yim A. Paradigm shift in surgical approaches to thymectomy. ANZ J Surg. 2002;72:40-5.
236. El-Dawlatly A, Al Kattan K, Hajjar W, Essa M, Delvi B, Khoja A. Anesthetic implications for video assisted thoracoscopic thymectomy in myasthenia gravis. Middle East J Anesthesiol. 2005;18:339-45.
237. Kalso E, Mennander S, Tasmuth T, Nilsson E. Chronic post-sternotomy pain. Acta Anaesthesiol Scand. 2001;45:935-9.
238. Roth T, Ackermann R, Stein R, Inderbitzi R, Rosler K, Schmid R. Thirteen years follow-up after radical transsternal thymectomy for myasthenia gravis. Do short-term results predict long-term outcome?. Eur J Cardiothorac Surg. 2002;21:664-70.
239. O'Riordan J, Miller D, Mottershead J, Hirsch N, Howard R. The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit. Eur J Neurol. 1998;5:137-42.
240. Wakayama Y, Ohbu S, Machida H. Myasthenia gravis, muscle twitch, hyperhidrosis and limb pain associated with thymoma: proposal of possible new myasthenic syndrome. Tohoku J Exp Med. 1991;164:285-91.
241. Cull R. Unilateral headache due to myasthenia gravis. Cephalalgia. 2003;23:556-7.
242. Rostedt A, Stalberg E. Joint pain and hyperalgesia due to pyridostigmine bromide in a patient with myasthenia gravis. Neurology. 2004;62:835-6.
243. Scheschonka A, Beuche W. Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. Pain. 2003;104:423-4.
244. Campbell W. The problem of pain and spasm in poliomyelitis as we see it on the wards of the Colorado General Hospital. Am J Phys Med. 1952;31:316-7.
245. Gersten J. Physiological aspects of the problem of pain and spasm in poliomyelitis. Am J Phys Med. 1952;31:317-20.
246. Levin S. Clinical aspects of the problem of pain and spasm in poliomyelitis. Am J Phys Med. 1952;31:332-7.
247. Whitehead R. Pharmacological aspects of the problem of pain and spasm in poliomyelitis. Am J Phys Med. 1952;31:321-3.
248. Shy G. Neurological aspects of the problem of pain and spasm in poliomyelitis. Am J Phys Med. 1952;31:323-5.
249. Dinken H. Physical medicine in pain and in spasm in poliomyelitis. Am J Phys Med. 1952;31:329-32.
250. Klein M, Keenan M, Esquenazi A, Costello R, Polansky M. Musculoskeletal pain in polio survivors and strength-matched controls. Arch Phys Med Rehabil. 2004;85:1679-83.
251. Budrys V. Neurological deficits in the life and works of Frida Kahlo. Eur Neurol. 2006;55:4-10.
252. On A, Oncu J, Uludag B, Ertekin C. Effects of lamotrigine on the symptoms and life qualities of patients with post polio syndrome: a randomized, controlled study. Neuro Rehabilitation. 2005;20:245-51.
253. Davenport R. Acute headache in the emergency department. J Neurol Neurosurg Psychiatry. 2002;72(Suppl 2):ii33-7.
254. Fitt G. Headache and hydrocephalus. Aust Fam Physician. 1998;27:194-5.
255. Rekate H, Yonas H, White R, Nulsen F. The acute abdomen in patients with ventriculoperitoneal shunts. Surg Neurol. 1979;11:442-5.
256. Arienta C, Sina C, Farabola M. Facial pain associated with hydrocephalus by aqueduct stenosis. Complete recovery after ventriculoatrial shunt. Case report. J Neurosurg Sci. 1986;30:81-2.
257. Findler G, Feinsod M. Reversible facial pain due to hydrocephalus with trigeminal somatosensory evoked response changes. Case report. J Neurosurg. 1982;57:267-9.
258. Tucker W, Fleming R, Taylor F, Schultz H. Trigeminal neuralgia in aqueduct stenosis. Can J Neurol Sci. 1978;5:331-303.
259. Gallagher A, Trounce J. Cerebral aqueduct stenosis presenting with limb pain. Dev Med Child Neurol. 1998;40:349-51.
260. Dias M, Li V, Pollina J. Low-pressure shunt 'malfunction' following lumbar puncture in children with shunted obstructive hydrocephalus. Pediatr Neurosurg. 1999;30:146-50.
261. Vetrugno R, Vella A, Mascalchi M, et al. Patching improves perfusion of the sagged brain in intracranial hypotension. J Neurol. 2011;258:146-8.
262. Gowers W. Epilepsy and other chronic convulsive diseases: their causes, symptoms and treatment. London: Churchill; 1901. p. 29-58.
263. Siegel A, Williamson P, Roberts D, Thadani V, Darcey T. Localized pain associated with seizures originating in the parietal lobe. Epilepsia. 1999;40:845-55.
264. Erickson J, Clapp L, Ford G, Jabbari B. Somatosensory auras in refractory temporal lobe epilepsy. Epilepsia. 2006;47:202-6.
265. Nair D, Najm I, Bulacio J, Luders H. Painful auras in focal epilepsy. Neurology. 2001;57:700-2.
266. Salanova V, Andermann F, Rasmussen T, Olivier A, Quesney L. Parietal lobe epilepsy. Clinical manifestations and outcome in 82 patients treated surgically between 1929 and 1988. Brain. 1995;118(Pt 3):607-27.
267. Yazawa S, Ikeda A, Sawamoto N, et al. Painful focal sensory seizure arising from the primary somatosensory cortex. Intern Med. 2003;42:875-9.
268. Kocher L, Rambaud L, Rousselle C, Mottolese C, Ryvlin P, Gonnaud P. Painful seizures with allodynia in an 11-year-old boy. Dev Med Child Neurol. 1999;41:704-7.
269. Akman C, Riviello J, Madsen J, Bergin A. Pharyngeal dysesthesia in refractory complex partial epilepsy: new seizure or adverse effect of vagal nerve stimulation?. Epilepsia. 2003;44:855-8.
270. Panayiotopoulos C. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J Neurol Neurosurg Psychiatry. 1999;66:536-40.
271. Benarroch EE. HCN channels: function and clinical implications. Neurology. 2013;80:304-10.
272. Liu Y, Lien W, Fang C, Lai T, Chen W, Wang H. ED presentation of acute porphyria. Am J Emerg Med. 2005;23:164-7.
273. Zinkin N, Peppercorn M. Abdominal epilepsy. Best Pract Res Clin Gastroenterol. 2005;19:263-74.
274. Hasan N, Razzaq A. Abdominal epilepsy. J Coll Physicians Surg Pak. 2004;14:366-7.
275. Levendorf M. Chronic abdominal pain and abdominal epilepsy. Am Fam Physician. 2000;61:50.
276. Kinton L, Johnson M, Smith S, et al. Partial epilepsy with pericentral spikes: a new familial epilepsy syndrome with evidence for linkage to chromosome 4p15. Ann Neurol. 2002;51:740-9.
277. Gottschalk A, Yaster M. The perioperative management of pain from intracranial surgery. Neurocrit Care. 2009;10:387-402.
278. Bloomfield E, Schubert A, Secic M, Barnett G, Shutway F, Ebrahim Z. The influence of scalp infiltration with bupivacaine on hemodynamics and postoperative pain in adult patients undergoing craniotomy. Anesth Analg. 1998;87:579-82.
279. Silberstein S, Olesen J, Bousser M, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)-revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25:460-5.
280. Dörffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002;359:849-50.
281. Muller EW, Girbes AR. Failure of subcutaneous vasopressin in diagnosis of central diabetes insipidus. Lancet. 1993;341:1037.
282. Newton M. Guidelines for the management of acute post-operative pain and related problems at NHNN. London: University College London Hospitals; 2002.
283. Straube S, Derry S, Moore RA, Wiffen PJ, McQuay HJ. Single dose oral gabapentin for established acute postoperative pain in adults. Cochrane Database Syst Rev. 2010:CD008183.
284. Dawson L, Brockbank K, Carr E, Barrett R. Improving patients' postoperative sleep: a randomized control study comparing subcutaneous with intravenous patient-controlled analgesia. J Adv Nurs. 1999;30:875-81.
285. Addonizio G, Susman V, Roth S. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987;22:1004-20.
286. Lo T, Unwin M, Dymock I. Neuroleptic malignant syndrome: another medical cause of acute abdomen. Postgrad Med J. 1989;65:653-5.
287. McDonough C, Swift G, Managan B, Sheehan J. Neuroleptic malignant syndrome: a diagnosis easily missed. Ir Med J. 2000;93:152-4.
288. Kadyan V, Colachis S, Depalma M, Sanderson J, Mysiw W. Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation. Brain Inj. 2003;17:631-7.
289. Haddow A, Harris D, Wilson M, Logie H. Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin. BMJ. 2004;329:1333-5.
290. Nachreiner R, Balledux J, Zieger M, Viegas O, Sood R. Neuroleptic malignant syndrome associated with metoclopramide in a burn patient. J Burn Care Res. 2006;27:237-41.
291. Aruna A, Murungi J. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. Ann Pharmacother. 2005;39:1131-5.
292. Kluger G, Kochs A, Holthausen H. Heterotopic ossification in childhood and adolescence. J Child Neurol. 2000;15:406-13.
293. Shapiro B, Warren J, Egol A, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Society of Critical Care Medicine. Crit Care Med. 1995;23:1596-2100.
294. American Pain Society: Principles of analgetic use in the treatment of acute pain and cancer pain. 4th ed. Glen-view: American Pain Society; 1998.
295. Jacobi J, Fraser G, Coursin D, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119-41.
296. French Society of Anesthesia and Intensive Care. Recommendations for sedation, analgesia and curarization. Short text. Ann Fr Anesth Reanim. 2000;19:98-105.
297. Standards and intents for sedation and anesthesia care. Comprehensive accreditation manual for hospitals. Oakbrook Terrace: Joint Commission on Accreditation of Healthcare Organization; 2001.
298. Liu L, Gropper M. Postoperative analgesia and sedation in the adult intensive care unit:a guide to drug selection. Drugs. 2003;63:755-67.
299. Acute pain management: operative or medical procedures and trauma. Clinical practice guideline. In: Acute Pain Management Guideline Panel. AHCPR Publication No. 92-0032. Agency for Health Care Policy and Research; 1992.
300. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002:CD003447.
301. Tipps L, Coplin W, Murry K, Rhoney D. Safety and feasibility of continuous infusion of remifentanil in the neurosurgical intensive care unit. Neurosurg Clin N Am. 2000;46:596-601
302. Ghoneim M, Mewaldt S. Benzodiazepines and human memory: a review. Anesthesiology. 1990;72:926-38.
303. Greenblatt D, Ehrenberg B, Gunderman J, et al. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther. 1989;250:134-40.
304. Shelly M, Mendel L, Park G. Failure of critically ill patients to metabolise midazolam. Anaesthesia. 1987;42:619-26.
305. Swart E, Zuideveld K, de Jongh J, Danhof M, Thijs L, Strack van Schijndel R. Comparative population pharmacokinetics of lorazepam and midazolam during. Br J Clin Pharmacol. 2004;57:135-45.
306. Barrientos-Vega R, Mar Sanchez-Soria M, Morales-Garcia C, Robas-Gomez A, Cuena-Boy R, Ayensa-Rincon A. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med. 1997;25:33-40.
307. Chamorro C, de Latorre F, Montero A, et al. Comparative study of propofol versus midazolam in the sedation of critically ill patients: results of a prospective, randomized, multicenter trial. Crit Care Med. 1996;24:932-9.
308. Knibbe C, Zuideveld K, DeJongh J, Kuks P, Aarts L, Danhof M. Population pharmacokinetic and pharmacodynamic modeling of propofol for. Clin Pharmacol Ther. 2002;72:670-84.
309. Swart E, van Schijndel R, van Loenen A, Thijs L. Continuous infusion of lorazepam versus medazolamin patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. Crit Care Med. 1999;27:1461-5.
310. McCollam J, O'Neil M, Norcross E, Byrne T, Reeves S. Continuous infusions of lorazepam, midazolam, and propofol for sedation of the critically ill surgery trauma patient: a prospective, randomized comparison. Crit Care Med. 1999;27:2454-8.
311. de Wildt S, de Hoog M, Vinks A, van der Giesen E, van den Anker J. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit Care Med. 2003;31:1952-8.
312. Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth. 1999;82:900-3.
313. Hamaoka N, Oda Y, Hase I et al. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. Clin Pharmacol Ther. 1999;66:110-7.
314. Gorski J, Jones D, Haehner-Daniels B, Hamman M, O'Mara EMJ, Hall S. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64:133-43.
315. Michalets E. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
316. McKeage K, Perry C. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs. 2003;17:235-72.
317. Kress J, O'Connor M, Pohlman A, et al. Sedation of critically ill patients during mechanical ventilation. A comparison of propofol and midazolam. Am J Respir Crit Care Med. 1996;153:1012-8.
318. Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001;357:117-8.
319. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?. Curr Pharm Des. 2010;16:488-501.
320. Hogarth D, Hall J. Management of sedation in mechanically ventilated patients. Curr Opin Crit Care. 2004;10:40-6.
321. Drazen J. COX-2 inhibitors - a lesson in unexpected problems. N Engl J Med. 2005;352:1131-2.
322. Okie S. Raising the safety bar - the FDA's coxib meeting. N Engl J Med. 2005;352:1283-5.
323. Couzin J. Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science. 2005;307:1183-5.
324. Mason L, Edwards J, Moore RA, McQuay HJ. Single dose oral indometacin for the treatment of acute post operative pain. Cochrane Database Syst Rev. 2004:CD004308.
325. Mason L, Edwards JE, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain. Cochrane Database Syst Rev. 2004:CD004234.
326. Daniels S, Melson T, Hamilton DA, Lang E, Carr DB. Analgesic efficacy and safety of a novel injectable formulation of diclofenac compared with intravenous ketorolac and placebo after orthopedic surgery: a multicenter, randomized, double-blinded, multiple dose trial. Clin J Pain. 2013;29(8):655-63.
327. Grimsby GM, Conley SP, Trentman TL, et al. A double-blind randomized controlled trial of continuous intravenous Ketorolac vs placebo for adjuvant pain control after renal surgery. Mayo Clin Proc. 2012;87:1089-97.
328. Leijon G, Boivie J. Central post-stroke pain - a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27-36.
329. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2005:CD005454.
330. Vestergaard K, Andersen G, Gottrup H, Kristensen B, Jensen T. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184-90.
331. Ostermann P, Westerberg C. Paroxysmal attacks in multiple sclerosis. Brain. 1975;98:189-202.
332. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev. 2005:CD005451.
333. Wiffen P, McQuay H, Edwards J, Moore R. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2005:CD005452.
334. Svendsen K, Jensen T, Bach F. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.
335. Jackson S, Pryce G, Diemel L, Cuzner M, Baker D. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience. 2005;134:261-8.
336. Pryce G, Ahmed Z, Hankey D, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain. 2003;127:2191-202.
337. Mandavilli A. Marijuana researchers reach for pot of gold. Nat Med. 2003;9:1227.
338. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2012. doi: 10.1016/j.jpainsymman.2012.07.014.
339. Scadding J, Wall P, Parry C, Brooks D. Clinical trial of propranolol in post-traumatic neuralgia. Pain. 1982;14:283-92.
340. Glynn C, Jamous M, Teddy P, Moore R, Lloyd J. Role of spinal noradrenergic system in transmission of pain in patients with spinal cord injury. Lancet. 1986;2:1249-50.
341. Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WRSTJ, Bellomo R. Dexmedetomidine vs haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009;13:R75.
342. Grof TM, Bledsoe KA. Evaluating the use of dexmedetomidine in neurocritical care patients. Neurocrit Care. 2010;12:356-61.
343. Tang JF, Chen PL, Tang EJ, May TA, Stiver SI. Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury. Neurocrit Care. 2011;15:175-81.
344. Shehabi Y, Nakae H, Hammond N, Bass F, Nicholson L, Chen J. The effect of dexmedetomidine on agitation during weaning of mechanical ventilation in critically ill patients. Anaesth Intensive Care. 2010;38:82-90.
345. Patel A, Davidson M, Tran MCJ, et al. Dexmedetomidine infusion for analgesia and prevention of emergence agitation in children with obstructive sleep apnea syndrome undergoing tonsillectomy and adenoidectomy. Anesth Analg. 2010;111:1004-10.
346. Edwards JE, McQuay HJ, Moore RA. Single dose dihydrocodeine for acute postoperative pain. Cochrane Database Syst Rev. 2000:CD002760.
347. Taylor W, Thomas N, Wellings J, Bell B. Timing of postoperative intracranial hematoma development and implications for the best use of neurosurgical intensive care. J Neurosurg. 1995;82:48-50.
348. Attal N, Gaude V, Brasseur L, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54:564-74.
349. Edmondson E, Simpson RKJ, Stubler D, Beric A. Systemic lidocaine therapy for poststroke pain. South Med J. 1993;86:1093-6.
350. Backonja M, Gombar K. Response of central pain syndromes of intravenous lidocaine. J Pain Symptom Manage. 1992;7:172-8.
351. Canavero S, Bonicalzi V, Pagni C, et al. Propofol analgesia in central pain: preliminary clinical observations. J Neurol. 1995;242:561-7.
352. Lampl C, Yazdi K, Roper C. Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke. 2002;33:3030-2.
353. Awerbuch G, Sandyk R. Mexiletine for thalamic pain syndrome. Int J Neurosci. 1990;55:129-33.
354. Shimodozono M, Kawahira K, Kamishita T, Ogata A, Tohgo S, Tanaka N. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci. 2002;112:1173-81.
355. Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol. 1998;40:191-200.
356. Holtom N. Gabapentin for treatment of thalamic pain syndrome. Palliat Med. 2000;14:167.